source
- Vaderis raises $152 million to launch late-stage trials of AKT inhibitor engasertib for rare bleeding disorderVaderis Therapeutics announced a $152 million Series B financing round, giving it sufficient capital to advance its experimental AKT-targeting drug, engasertib. The company has also begun late-sta…
- Aura Biosciences cuts 20% of staff and reshuffles C-suite to focus on ocular oncologyAura Biosciences announced it is eliminating about one-fifth of its workforce as part of a broader restructuring under its new chief executive officer, Natalie Holles, who took the helm in April.…